— Clovis Oncology (NASDAQ: CLVS) reported a fourth-quarter 2019 loss of $1.81 per share versus a loss of $1.71 per share expected.
— Product revenues grew by 30% to $39.3 million versus $38.97 million expected. The top line was driven by an increase in the US net product revenue.
![Earnings Update by AlphaStreet](https://cdn.news.alphastreet.com/wp-content/uploads/2019/04/Earnings-Coverage-4-1024x768.jpg)
— The supply of free drugs distributed to eligible patients in the U.S. through the Rubraca patient assistance program for Q4 2019 was 18% of the overall US commercial supply, compared to 26% reported in Q4 2018.
— Research and development expenses increased by 2% year-over-year due primarily to higher research and development costs for rucaparib clinical trials.
— The company believes it has sufficient cash, cash equivalents, and available-for-sale securities to fund its operating plan into the second half of 2021. This is based on anticipated revenue, spending, available financing sources, and existing cash.
Most Popular
CL Earnings: Key quarterly highlights from Colgate-Palmolive’s Q2 2024 financial results
Colgate-Palmolive Company (NYSE: CL) reported its second quarter 2024 earnings results today. Net sales increased 4.9% year-over-year to $5 billion. Organic sales increased 9%. Net income attributable to Colgate-Palmolive Company was $731
Key takeaways from Visa’s Q3 2024 earnings report
Credit card behemoth Visa, Inc. (NYSE: V) this week reported mixed results for the June quarter, with earnings matching expectations and sales slightly missing the view. Both numbers grew in
Southwest Airlines (LUV): A look at the airline’s performance in Q2 2024
Shares of Southwest Airlines Co. (NYSE: LUV) were up over 6% on Thursday after the company beat earnings estimates for the second quarter of 2024. The stock has gained 4%